Double-blind Comparative Study of TAK-875.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2018
At a glance
- Drugs Fasiglifam (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 28 Feb 2018 Results of an integrated pooled analysis (n=9139) assessing the hepatic safety of fasiglifam from the data of 15 double-blind studies from both global and Japanese development programs (six phase II and nine phase III) including this study, published in the Drug Safety Journal.
- 10 Jun 2017 Biomarkers information updated
- 24 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History